The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers

Boston, MA and Rolle, Switzerland, January 28, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has unveiled the OncoPortal™ Mutation Tracker— a longitudinal MRD tracking tool designed for disease monitoring in the context of oncology. This innovation underscores SOPHiA GENETICS’ commitment to advancing data-driven approaches for improved oncology insights.

Tracking genomic variants across multiple time points in the same patient is becoming increasingly critical in cancer care, particularly for identifying treatment resistance or detecting residual cancer cells, such as in Measurable Residual Disease (MRD) management. The integration of longitudinal tracking capabilities with next-generation sequencing (NGS) allow the parallel detection of cancer-specific genetic mutations at very low frequencies. This combined approach enables early identification of residual disease or emerging variants, providing a more precise assessment of disease burden, better stratification of high-risk patients, and the ability to tailor treatments to the cancer’s unique genomic profile.

The OncoPortal™ Mutation Tracker augments the SOPHiA DDM™ Platform’s core analytical capabilities to allow clinical researchers to longitudinally monitor evolving genomic variants across multiple time points, providing a comprehensive view of disease evolution. The OncoPortal™ Mutation Tracker enhances workflow efficiency for longitudinal variant tracking by offering flexible low frequency variant selection, customizable threshold settings, and reporting features to generate longitudinal graphical representations, simplifying the process of tracking and analyzing genetic changes over time.

“This longitudinal interface represents the solution we've been seeking to unite our oncologists in 
embracing broader adoption of NGS. It's the missing piece that unlocks a new frontier in personalized, data-driven medicine,” said Dr. Christophe Marzac Head of the Hematology-Immunology Unit Gustave Roussy Institute.

For more information on the OncoPortal™ Mutation Tracker, visit SOPHiAGENETICS.com.

About SOPHiA GENETICS 

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

Media Contact: 

Kelly Katapodis
[email protected]